Search

Asebio has brought together 60 investors interested in Spanish biotech projects from 9 countries. More than five-hundred opportunities for companies participating in partnering meetings

Given the situation caused by the Covid-19 pandemic, with the recommendations of healthcare authorities in mind and foreseeing the situations that may arise over the remainder of 2020, AseBio decided

The National Center for Biotechnology-CSIC, the Carlos III Health Institute and the Biomedical Research Institute (IRB Barcelona), are three of the eight Spanish research centers that participate in

3P Biopharmaceuticals together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against

Agreement strengthens collaboration between the companies following submission of the first dossier to the European Medicines Agency (EMA) for a CrisBio® produced recombinant vaccine

ZeClinics SL, announced today that they have entered into a joint research agreement with Taros Chemicals GmbH.

Two Cardiovascular R&D Heavyweights Aim to Tackle Ischemic Heart Disease with Novel Cardiac Regeneration Strategy.

License Agreement for the Commercialisation of Zebrafish model for Childhood Epilepsy Will Provide New Opportunities for Novel Antiepileptic Drug Discovery.

It´s for the project “UNLOCK-EDD: UNLOCK next generation computer guided Enzyme Discovery & Design”

XIIIth Spanish-Portuguese Conference on Controlled Drug Delivery will be held from January 22-24th, 2020 at the University of Santiago de Compostela

One of our goals is to count on the best professionals in order to offer excellence in our services and products.

The Spanish Association of Biocompanies (AseBio) has chosen the capital of Navarra to host the tenth edition of the event, which will be held from 29 September to 1 October.

Bayer Animal Health GmbH and VLPbio - The Vaccines Company S.L. have signed a global collaboration agreement to discover and develop a new generation of immunotherapeutic solutions that address the

Potential approval would validate the use of Algenex’ CrisBio® technology for the manufacture of recombinant subunit vaccines

Asebio Investor Day, meeting point for specialized biotechnology investment

The 25th anniversary of BIO-Europe takes place in Hamburg on November 11-13

VIVEbiotech will now have 600 square meters of clean rooms with 8 nanobioreactors and two large capacity bioreactors.

Within the framework of Bio €quity 2019, Asebio advances that investment in the biotech sector reached historical highs in 2018.